Immunogenicity poses a critical risk to all biologics -  including monoclonal antibodies, ADCs, recombinant proteins, cell & gene therapies, and mRNA-based therapies. The consequences of immunogenicity can not only endanger patients, but also reduce the treatment's effectiveness. A central component of the immune response to a protein is the activation of CD4+ T cells, which occurs when peptides from the protein bind to HLA receptors  and subsequently engage the TCR and trigger T cell activation.

This webinar explores how a cutting-edge, high-sensitivity in vitro immunopeptidomics assay (MHC-Associated Peptide Proteomics (or “MAPPs”)), can identify regions within therapeutic proteins that are prone to HLA binding. Thus helping to assess the sequence-based risk of activating a T cell response, which is a key factor in preclinical immunogenicity risk assessments. By integrating the MAPPs assay into your development pipeline, you can enhance lead selection, optimize candidates, and investigate known immunogenicity challenges. 

We will present a case study demonstrating how this assay helped identify the root cause of immunogenicity in a novel ADC that showed high levels of immunogenicity in early clinical trials. Join us to learn how this advanced assay can support a more informed and proactive approach to immunogenicity risk assessment in biologics development.